809 abstracts found.



Results filter

CAL‑101 (GS‑1101)-based targeted therapy in Mantle Cell Lymphoma (MCL), Indolent Non-Hodgkin Lymphoma (iNHL) and Chronic Lymphocytic Leukaemia (CLL)

Year:

Session type:

Thomas Jahn1
1Gilead Sciences, Inc., Seattle, WA, United States Minor Outlying Islands

Class III phosphatidylinositol 3-kinase as tumour suppressor

Year:

Session type:

Harald Stenmark1
1The Norwegian Radium Hospital, Oslo, Norway

Direct and indirect actions of PI 3-kinase in cancer

Year:

Session type:

Bart Vanhaesebroeck1
1Barts Cancer Centre, London, UK

Introduction: Prognostication in advanced cancer: How and why?

Year:

Session type:

John Ellershaw1
1University of Liverpool & Marie Curie Palliative Care Institute

Promising new drugs in lymphoma – opportunities for changing practice

Year:

Session type:

Bruce D. Cheson1
1Georgetown Lombardi Comprehensive Cancer Center, Washington, USA

The use of prognostic tools in palliative care

Year:

Session type:

Paddy Stone1
1St George's University, London, UK

Reduced intensity allogeneic transplantation for relapsed lymphoma

Year:

Session type:

Stephen Mackinnon1
1University College Hospital, London, UK

Dialogues to improve end of life care: prognostication and advance care planning

Year:

Session type:

Jane Seymour1
1University of Nottingham, Nottingham, UK

Late treatment effects in patients with lymphoma – their impact on the duration and quality of survival

Year:

Session type:

Flora van Leeuwen1
1The Netherlands Cancer Institute

Diagnosing dying: Findings of a European Collaborative Study OPCARE9

Year:

Session type:

John Ellershaw1
1University of Liverpool & Marie Curie Palliative Care Institute

Introduction:  Liver and colorectal cancer

Year:

Session type:

Tim Maughan1
1Gray Institute for Radiation Oncology and Biology, Oxford, UK

Integrated genomic analyses of glioblastoma multiforme: An update from The Cancer Genome Atlas

Year:

Session type:

Roeland Verhaak1
1MD Anderson Cancer Center, Houston, TX, USA

Biomarker-driven stratification of medulloblastoma therapy through international clinical trials

Year:

Session type:

Steve Clifford1
1Newcastle University, Newcastle-upon-Tyne, UK

Health-related quality of life in brain tumour patients

Year:

Session type:

Martin J.B. Taphoorn1
1Medical Centre Haaglanden, The Hague, The Netherlands

Introduction: Raising awareness of cancer research: The role of education

Year:

Session type:

David Ardron1
1National Cancer Research Institute Consumer Liaison Group, London, UK

The ‘Centre of the Cell’ and its role in science education

Year:

Session type:

Frances Balkwill1
1Barts Cancer Institute, London, UK

Health research in primary education from the Medicines For Children Research Network

Year:

Session type:

Tina Simpson1
1Medicines For Children Research Network

Can we teach it? Yes, we CAM!  –  A cancer awareness research project at The Thomas Alleyne School, Stevenage

Year:

Session type:

Richard Stephens1
1The Thomas Alleyne School, Stevenage, UK

Introduction: Chernobyl: Fact from fiction – the benefit of 25 years hindsight and integrated research

Year:

Session type:

Geraldine Thomas1
1Chernobyl Tissue Bank & Imperial College, London, UK

Clinical outcomes in radiation-induced thyroid cancer

Year:

Session type:

Michael Tuttle1
1Memorial Sloan-Kettering Cancer Center, New York, USA

The epidemiology of radiation-induced thyroid disease

Year:

Session type:

Elisabeth Cardis1
1The Centre for Research in Environmental Epidemiology

Comparative logical models of signaling networks in normal and transformed hepatocytes

Year:

Session type:

Julio Saez-Rodriguez1
1European Bioinformatics Institute, Cambridge, UK

Managing environmental monitoring programmes following a major nuclear accident

Year:

Session type:

Paul Leonard1
1Exeter University, EXETER, UK

Introduction: Lifestyle factors in cancer prevention

Year:

Session type:

Laurence Moore1
1Cardiff University, Cardiff, UK

Introduction: Improving patient outcomes in lymphoma

Year:

Session type:

John Radford1
1University of Manchester, Manchester, UK

Diet and cancer: Some current controversies

Year:

Session type:

Kay-Tee Khaw1
1University of Cambridge, Cambridge, UK

Diet and physical activity for cancer risk reduction – opportunities for endorsing lifestyle change

Year:

Session type:

Annie Anderson1
1University of Dundee, Scotland, UK

TREC – A transdisciplinary approach to obesity and cancer research

Year:

Session type:

Linda Nebeling1
1National Cancer Institute, Bethesda, USA

Introduction: New insights into the biology and management of brain tumours

Year:

Session type:

Susan Short1
1University College London, London, UK

Evidence supporting palliative care interventions

Year:

Session type:

Michael Bennett1
1University of Leeds

Effect of earlier palliative care intervention on patients with advanced lung cancer

Year:

Session type:

Jennifer Temel1
1Massachusetts General Hospital

Short-term palliative care – a new model for the new trajectories in cancer: Development and evaluation

Year:

Session type:

Irene J. Higginson1
1King's College London, London, UK

Introduction: Immune control of cancer

Year:

Session type:

Caetano Reis e Sousa1
1Cancer Research UK London Research Institute, London, UK

Lymphoid stress-surveillance – toxins, allergies, and tumour surveillance

Year:

Session type:

Adrian Hayday1
1CR-UK London Research Institute, London, UK

Cancer immunoediting: Immunologic control and shaping of cancer

Year:

Session type:

Robert Schreiber1
1Washington University School of Medicine, Saint Louis, MO, USA

Intratumoral immune reaction: A novel paradigm for cancer

Year:

Session type:

Jérôme Galon1
1INSERM, Paris, France

Introduction: Moving towards a molecular rather than a risk-based approach to selecting breast cancer patients who won’t benefit from standard treatment

Year:

Session type:

David Cameron1
1Edinburgh Cancer Research Centre, Edinburgh, UK

Introduction: Integrating knowledge for the new age: Cancer informatics

Year:

Session type:

Bissan Al-Lazikani1
1Institute of Cancer Research, Surrey, UK

Reducing the burden of breast radiotherapy

Year:

Session type:

John Yarnold1
1Insititute of Cancer Research & Royal Marsden Hospital, Sutton, UK

Chemical biology informatics in compound MOA elucidation

Year:

Session type:

Jeremy Jenkins1
1Novartis, Cambridge, MA, USA

Patient and treatment selection in the era of genomic taxonomy of breast cancer

Year:

Session type:

Luca Gianni1
1San Raffaele Hospital

Elucidating clinically relevant gene fusions from transcriptome sequencing data

Year:

Session type:

Christopher Maher1
1Washington University, St. Louis, MO, USA

Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: Visualising the therapeutic effects of metformin in tumour tissue

Year:

Session type:

Michael Lisanti1
1Kimmel Cancer Center, Philadelphia, PA, USA

Introduction: Cell senescence

Year:

Session type:

Jesus Gil1
1MRC Clinical Sciences Centre, London, UK

A negative-feedback signalling network

Year:

Session type:

Karen Cichowski1
1Brigham and Women's Hospital

Oncogene-induced senescence: not all oncogenes are equal

Year:

Session type:

Peter D. Adams1
1Institute of Cancer Sciences, Glasgow, UK

Senescence surveillance in hepatocellular carcinoma

Year:

Session type:

Lars Zender1
1Helmholtz Centre for Infection Research, Braunschweig, Germany

Introduction: Earlier intervention by palliative care: translating evidence into practice

Year:

Session type:

Mike Bennett1
1University of Leeds, Leeds, UK

A phase I dose escalation study of oral MK-2206 (Allosteric AKT Inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK Inhibitor) in patients with advanced or metastatic solid tumours

Year:

Session type:

Johann de Bono2, Richard Baird2, Amita Patnaik1, Victor Moreno-Garcia2, Kyriakos Papadopoulos1, Chris.R Garrett3, David Olmos2, Keith A Shannon4, Victoria Zazulina5, Eric Rubin4, Ian Smith5, Jane Ryan5, Paul Smith3, Adekemi B Taylor4, Maria Learoyd5, Lisa Lupinacci4, Li Yan4, Anthony Tolcher1
1START, San Antonio, TX, USA, 2Royal Marsden Hospital/ Institute of Cancer Research, Sutton, Surrey, UK, 3University of Texas M.D Anderson Cancer Center, Houston, TX, USA, 4Merck Sharp & Dohme Corp, North Wales, PA, USA, 5AstraZeneca, Macclesfield, Cheshire, UK

A randomised phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN53643604)

Year:

Session type:

Robert A Huddart1, Rhian Gabe2, Fay H Cafferty2, Philip Pollock3, Jeff D White4, Jonathan Shamash5, Sally P Stenning2
1Institute of Cancer Research, Sutton, Surrey, UK, 2Medical Research Council Clinical Trials Unit, London, UK, 3Cancer Research UK and UCL Cancer Trials Centre, London, UK, 4Beatson West of Scotland Cancer Centre, Glasgow, UK, 5St Bartholomew's Hospital, London, UK